{
    "clinical_study": {
        "@rank": "89102", 
        "arm_group": {
            "arm_group_label": "Pegylated liposomal doxorubicin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Primary Objective: To evaluate if low BRCA1 protein expression has a preferential effect on\n      response when metastatic breast cancer patients are treated with DNA damaging chemotherapy\n      agent, compared to historical controls\n\n      Secondary Objective: To evaluate if low BRCA1 protein expression has a preferential effect\n      on tumor progression when metastatic breast cancer patients are treated with DNA damaging\n      chemotherapy agent, compared to historical controls"
        }, 
        "brief_title": "Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Metastatic breast cancer and have formalin-fixed, paraffin embedded primary tumor\n             available for testing BRCA1 protein expression\n\n          -  Adults over 18 years of age\n\n          -  Have resolution of all acute toxic effects of any prior chemotherapy or radiotherapy\n             to NCI CTC grade \u2264 1 prior to study registration.\n\n          -  Be informed of the investigational nature of this study and provide written informed\n             consent in accordance with institutional and federal guidelines prior to study\n             specific screening procedures\n\n          -  Be willing and able to comply with the treatment plan, scheduled clinic visits,\n             laboratory and oncological tests and other study procedures\n\n          -  Have a ECOG performance status of 0 - 2\n\n          -  Measurable disease by CT by RECIST 1.1 to evaluate response\n\n          -  Adequate bone marrow function defined as platelets 100 X 109 cells/L, neutrophils 1.5\n             x 109 cells/L, white blood cells (WBC) 3.0 x 109 cells/L and a hemoglobin 90 gm/L\n\n          -  Creatinine < 1.5 mg/dl or creatinine clearance > 40 ml/min\n\n          -  Liver function tests (AST and or ALT) should be 2 x upper limit of normal (ULN,\n             defined as per laboratory where blood testing is done), total bilirubin 1.5 x ULN\n             (except for patients with liver metastases, ALT and/or ALT 5 times the upper limit of\n             normal is accepted)\n\n        Exclusion Criteria:\n\n          -  Myocardial infarction within 6 months of registration\n\n          -  Brain metastases unless documented to be controlled post completion of local therapy\n             (surgery and/or radiation therapy) for at least four weeks prior to registration\n\n          -  Pregnant or breast feeding women. Women with child bearing potential must use\n             effective measures to prevent pregnancy while receiving pegylated liposomal\n             doxorubicin\n\n          -  Have a concurrent active non-breast malignancy except for non-melanoma skin cancer\n\n          -  Her2 positive tumors as defined by FDA guidelines(3+ immunohistochemical staining,\n             defined as uniform, intense membrane staining of more than 10% of invasive tumor\n             cells, and for cases with 2+ staining showing gene amplification by FISH, expressed\n             as a ratio of more than 2 when comparing HER-2 gene and chromosome 17 fluorescent\n             signals)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990352", 
            "org_study_id": "1300000710"
        }, 
        "intervention": {
            "arm_group_label": "Pegylated liposomal doxorubicin", 
            "intervention_name": "Pegylated liposomal doxorubicin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Doxorubicin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 24, 2014", 
        "location": {
            "contact": {
                "email": "DLewallen@uacc.arizona.edu", 
                "last_name": "Dana Lewallen", 
                "phone": "520-626-2175"
            }, 
            "facility": {
                "address": {
                    "city": "Tucson", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85742"
                }, 
                "name": "University of Arizona Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Arm Phase II Trial to Assess Association of BRCA1 Protein Expression With Overall Response Rate in Patients With Metastatic Breast Cancer on Pegylated Liposomal Doxorubicin", 
        "overall_contact": {
            "email": "DLewallen@uacc.arizona.edu", 
            "last_name": "Dana Lewallen", 
            "phone": "520-626-2175"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluating if low BRCA1 protein expression has a preferential effect on response when metastatic breast cancer patients are treated with DNA damaging chemotherapy agent, compared to historical controls.  Response rate is defined as the percentage of evaluable patients who achieve complete response (CR) or partial response (PR) as measured by RECIST 1.1 on CT or PET/CT as the best overall response.", 
            "measure": "Overall response rate for metastatic breast cancer patients with low BRCA1 protein expression in their tumor, treated with pegylated liposomal doxorubicin", 
            "safety_issue": "No", 
            "time_frame": "Start of treatment and repeat imaging done at 9 weeks (\u00b1 7 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990352"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Evaluating if low BRCA1 protein expression has a preferential effect on tumor progression when metastatic breast cancer patients are treated with DNA damaging chemotherapy agent, compared to historical controls.  Progression free survival will be measured as the times from the start of pegylated liposomal doxorubicin to the time the patient is first recorded as having disease progression or dies. If a patient does not progress or die while being followed via tumor assessment, progression-free survival will be censored at the time of last disease assessment. The median progression free survival will be calculated in patients with low BRCA1 protein expression and intact BRCA1 protein expression. Median progression free survival will be estimated by Kaplan-Meier methodology", 
            "measure": "Progression free survival for patients with breast cancer with low BCRCA1 protein expression treated with pegylated liposomal doxorubicin", 
            "safety_issue": "No", 
            "time_frame": "Start of Treatment until the date of first documented progression or date of death, assessed up to  an expected average of 100 weeks"
        }, 
        "source": "University of Arizona", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Arizona", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}